

## Geptanolimab

Cat. No.:	HY-P99639
CAS No.:	2348469-43-0
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer <sup>[1]</sup> .
<b>In Vitro</b>	Geptanolimab (CBT-501) has highly specific binding to PD-1 of human ( $K_D=505$ pM) and cynomolgus ( $K_D=7.2$ nM) <sup>[1]</sup> . Geptanolimab enhances human T-cell activation in the Mix Lymphocyte Reaction (MLR), increasing release of IL-2 and INF- $\gamma$ <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Geptanolimab (ip; once every two weeks, for 6 weeks; mice with MC38 syngeneic tumor models) has anti-tumor activity and tumor inhibition rate reached 83% <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Qing Z, et, al. Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma. Journal of Clinical Oncology. 2017;35 (7\_suppl):108-108.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA